Controlling and preventing Asthma progression and Severity in Kids (CASK)
控制和预防儿童哮喘进展和严重程度 (CASK)
基本信息
- 批准号:9189905
- 负责人:
- 金额:$ 284.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-20 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:3 year oldAddressAdultAffectAftercareAgeAllergensAllergicAntibodiesAntibody FormationAsthmaAttenuatedBirthChildChildhoodChildhood AsthmaChronicCohort StudiesDevelopmentDiagnosisDiseaseDisease ProgressionDouble-Blind MethodEnvironmental ExposureExposure toFundingFutureHypersensitivityIgEImmune responseImpairmentInflammationInterferon-alphaInterleukin-13Interleukin-4Interleukin-5InterventionLeadLifeLower Respiratory Tract InfectionMediatingMorbidity - disease rateNational Institute of Allergy and Infectious DiseaseNatural HistoryParticipantPathway interactionsPharmaceutical PreparationsPhenotypePlacebo ControlPlacebosPredispositionPrevalencePreventionProductionProtocols documentationPublic HealthQuality of lifeRandomizedReactionRegulatory T-LymphocyteResearch PersonnelRhinovirusRiskRisk FactorsRoleSamplingSchool-Age PopulationSeasonsSeveritiesSignal TransductionSocietiesSourceSteroidsT-LymphocyteTestingUnited StatesViralVirus DiseasesWheezingWitabstractingagedairborne allergenallergic responseanti-IgEasthma preventioncohortcostcrosslinkcytokinedesigndisabilityearly childhoodenvironmental allergenhealth care service utilizationhigh riskmast cellmortalitynovel strategiesomalizumabpreventprimary outcomeresponsesecondary outcometreatment group
项目摘要
Project Summary/Abstract
Asthma remains one of the most important challenges to pediatric public health in the US, affecting millions of
children, causing significant morbidity, mortality, and source of tremendous financial burden. Prevention of
asthma is a pressing, unmet need of utmost priority. The vast majority of children with persistent and chronic
asthma demonstrate aeroallergen sensitization (IgE antibody production), which remains the pivotal risk factor
for developing persistent, progressive asthma throughout life. It has recently been shown that aeroallergen
sensitization precedes viral wheezing and is the pivotal causal pathway and essential susceptibility factor in the
persistence and progression of the disease. Most aeroallergen sensitization begins around the age of 2-3
years and escalates during school age. The progression appears to be dependent on exposures to offending
allergens-- the greatest increase in development and impairment from asthma is seen in those with a tendency
toward Type 2 inflammation who are sensitized and exposed to high levels of offending allergens. In addition
to its role in mediating allergen-induced responses, IgE signals impair innate anti-viral immune responses
which could lead to increased viral infections and thus potentially further enhance the cascade of progression
to asthma. Omalizumab (anti-IgE) markedly reduces asthma exacerbations during the viral season and anti-
IgE treated children have demonstrated restored IFN-α response to rhinovirus. This suggests that anti-IgE
prevents IgE driven responses to offending allergen exposure in those with a Type 2 phenotype AND
attenuates viral infections in this Type 2 phenotype. Thus, utilizing anti-IgE in young children has the potential
to prevent the development of established asthma in susceptible children by blocking all IgE allergen-antibody
interactions (including responses to subclinical exposures) AND by reducing the response to viral exposure
which may lead to asthma. We hypothesize that blockade of IgE in young children (age 2-3) at high risk for
development of asthma will prevent progression to established asthma. We will test this hypothesis by
examining the effect of anti-IgE on the development of asthma in a double-blind, randomized, placebo-
controlled parallel trial of anti-IgE vs placebo in 250 children aged 2-3 years old at high risk of developing
asthma, who will be followed for 2 years after 2 years of therapy is discontinued. Primary outcome will be the
proportion of participants with current, active asthma as defined in the NIAID URECA birth cohort, between the
two treatment groups at the end of Year 4, the final 12 months of the trial off study medication. Secondary
outcomes will include occurrence of wheezing episodes, exacerbations requiring steroids, and new and
persistent allergen-specific IgE sensitizations after IgE therapy. If confirmed, anti-IgE therapy would be the first
intervention to change the natural history of childhood asthma. This trial will not only allow us to expand our
understanding of asthma immunopathogenesis, but will also create opportunities to identify IgE mediated and
other novel approaches impacting our understanding towards preventing the disease.
项目概要/摘要
哮喘仍然是美国儿科公共卫生面临的最重要挑战之一,影响着数百万儿童
儿童,造成显着的发病率、死亡率,并造成巨大的经济负担。预防
哮喘是一个迫切且未得到满足的首要需求。绝大多数儿童患有持续性和慢性的
哮喘表现出空气过敏原致敏(IgE 抗体产生),这仍然是关键的危险因素
用于终生发展为持续性、进行性哮喘。最近的研究表明,空气过敏原
致敏先于病毒性喘息,是病毒性喘息的关键因果途径和重要的易感因素。
疾病的持续性和进展。大多数空气过敏原敏化开始于 2-3 岁左右
年并在学龄期间升级。进展似乎取决于接触犯罪的情况
过敏原——有过敏原倾向的人,哮喘的发育和损害最大程度增加
2 型炎症,即过敏并暴露于高水平的过敏原。此外
由于其在介导过敏原诱导反应中的作用,IgE 信号会损害先天抗病毒免疫反应
这可能导致病毒感染增加,从而可能进一步增强级联进展
哮喘。奥马珠单抗(抗 IgE)可显着减少病毒季节期间的哮喘发作,并可抗
经过 IgE 治疗的儿童对鼻病毒的 IFN-α 反应已恢复。这表明抗 IgE
防止具有 2 型表型的人对有害过敏原暴露产生 IgE 驱动的反应并且
减弱这种 2 型表型的病毒感染。因此,在幼儿中使用抗 IgE 具有潜力
通过阻断所有 IgE 过敏原抗体来预防易感儿童发生哮喘
相互作用(包括对亚临床暴露的反应)以及减少对病毒暴露的反应
这可能会导致哮喘。我们假设幼儿(2-3 岁)的 IgE 阻断具有以下风险:
哮喘的发展将防止进展为已形成的哮喘。我们将通过以下方式检验这个假设
在一项双盲、随机、安慰剂研究中检查抗 IgE 对哮喘发展的影响
在 250 名 2-3 岁高风险儿童中进行抗 IgE 与安慰剂对照平行试验
哮喘患者,在停止治疗 2 年后将随访 2 年。主要结果将是
患有 NIAID URECA 出生队列中定义的当前活动性哮喘的参与者比例
两个治疗组在第 4 年末,即试验的最后 12 个月,停止研究药物治疗。中学
结果将包括出现喘息发作、需要类固醇的病情加重以及新的和
IgE 治疗后持续的过敏原特异性 IgE 致敏。如果得到证实,抗 IgE 治疗将是首选
干预改变儿童哮喘的自然史。这次试验不仅使我们能够扩大我们的
了解哮喘免疫发病机制,同时也将创造机会识别 IgE 介导的和
其他影响我们对预防这种疾病的理解的新方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WANDA PHIPATANAKUL其他文献
WANDA PHIPATANAKUL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WANDA PHIPATANAKUL', 18)}}的其他基金
School Inner-City Asthma Intervention Study : Human Epidemiology and Response to SARS-COV-2 (HEROS) Supplement
学校内城区哮喘干预研究:人类流行病学和对 SARS-COV-2 (HEROS) 补充剂的反应
- 批准号:
10162929 - 财政年份:2020
- 资助金额:
$ 284.35万 - 项目类别:
Controlling and preventing Asthma progression and Severity in Kids (CASK)
控制和预防儿童哮喘进展和严重程度 (CASK)
- 批准号:
10431970 - 财政年份:2016
- 资助金额:
$ 284.35万 - 项目类别:
Controlling and preventing Asthma progression and Severity in Kids (CASK)
控制和预防儿童哮喘进展和严重程度 (CASK)
- 批准号:
10215240 - 财政年份:2016
- 资助金额:
$ 284.35万 - 项目类别:
Controlling and preventing Asthma progression and Severity in Kids (CASK)
控制和预防儿童哮喘进展和严重程度 (CASK)
- 批准号:
10074697 - 财政年份:2016
- 资助金额:
$ 284.35万 - 项目类别:
Controlling and preventing Asthma progression and Severity in Kids (CASK)
控制和预防儿童哮喘进展和严重程度 (CASK)
- 批准号:
9318449 - 财政年份:2016
- 资助金额:
$ 284.35万 - 项目类别:
Midcareer Investigator Award: Urban School Allergen Exposures and Childhood Asthm
职业生涯中期调查员奖:城市学校过敏原暴露和儿童哮喘
- 批准号:
9064061 - 财政年份:2013
- 资助金额:
$ 284.35万 - 项目类别:
K24: Midcareer Investigator Award: Urban School Allergen Exposure and Childhood Asthma
K24:职业生涯中期研究员奖:城市学校过敏原暴露和儿童哮喘
- 批准号:
9920076 - 财政年份:2013
- 资助金额:
$ 284.35万 - 项目类别:
Midcareer Investigator Award: Urban School Allergen Exposures and Childhood Asthm
职业生涯中期调查员奖:城市学校过敏原暴露和儿童哮喘
- 批准号:
8667990 - 财政年份:2013
- 资助金额:
$ 284.35万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 284.35万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 284.35万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 284.35万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 284.35万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 284.35万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 284.35万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 284.35万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 284.35万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 284.35万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 284.35万 - 项目类别:
Research Grant